98%
921
2 minutes
20
The D-aspartate oxidase (DDO) gene encodes the enzyme responsible for the catabolism of D-aspartate, an atypical amino acid enriched in the mammalian brain and acting as an endogenous NMDA receptor agonist. Considering the key role of NMDA receptors in neurodevelopmental disorders, recent findings suggest a link between D-aspartate dysmetabolism and schizophrenia. To clarify the role of D-aspartate on brain development and functioning, we used a mouse model with constitutive Ddo overexpression and D-aspartate depletion. In these mice, we found reduced number of BrdU-positive dorsal pallium neurons during corticogenesis, and decreased cortical and striatal gray matter volume at adulthood. Brain abnormalities were associated with social recognition memory deficit at juvenile phase, suggesting that early D-aspartate occurrence influences neurodevelopmental related phenotypes. We corroborated this hypothesis by reporting the first clinical case of a young patient with severe intellectual disability, thought disorders and autism spectrum disorder symptomatology, harboring a duplication of a chromosome 6 region, including the entire DDO gene.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343392 | PMC |
http://dx.doi.org/10.1038/s41398-022-02088-5 | DOI Listing |
Biomed Pharmacother
August 2025
Shanghai Traditional Chinese Medicine Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; State Key Laboratory of S
Serine is a non-essential amino acid that supports multiple key metabolic processes, including the synthesis of proteins, amino acids, and glutathione. The central or peripheral dysregulation of serine metabolism in patients with depression has sparked interest in targeted treatment of serine metabolism, particularly D-amino acid oxidase (DAAO) and neuroactive metabolites such as phosphatidylserine (PS), creatine, and sarcosine. This article elaborates on the synthesis and metabolic pathways of serine, including a series of metabolites involved in pathological processes such as excitotoxicity and neuroinflammation, which are closely related to depression.
View Article and Find Full Text PDFCNS Neurol Disord Drug Targets
July 2025
Department of Research and Development, SyneuRx International (Taiwan) Corp., New Taipei City, Taiwan.
Introduction: Sodium benzoate (NaBen), a D-amino acid oxidase inhibitor, has been demonstrated to possess antipsychotic and cognition-enhancing effects in animal models. However, the clinical findings in patients with schizophrenia and dementia are mixed and inconclusive.
Objectives: To further improve its therapeutic potential, a novel crystalline polymorph of NaBen (abbreviated as Ω-NaBen) was developed.
Int J Mol Sci
May 2025
Department of Neurosciences, Discipline of Psychiatry and Pediatric Psychiatry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400394 Cluj-Napoca, Romania.
Schizophrenia is a complex neuropsychiatric disorder composed of primary cluster-positive symptoms, negative symptoms, disorganization, neurocognitive deficits, and social cognitive impairments. While traditional antipsychotics primarily target dopamine pathways, they provide limited efficacy against cognitive deficits and negative symptoms. Growing evidence implicates glutamatergic dysregulation, particularly N-methyl-D-aspartate receptor (NMDA-R) hypofunction, in the pathophysiology of schizophrenia, making glutamate modulation a promising therapeutic approach.
View Article and Find Full Text PDFMedicina (Kaunas)
March 2025
Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. : Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were reviewed according to the results from Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study and systematic reviews. For the rest of the antidepressants, a PubMed/Medline search was conducted with priority for systematic reviews.
View Article and Find Full Text PDFInt J Neuropsychopharmacol
December 2024
Neurocrine Biosciences, Inc., San Diego, CA, United States.
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been proposed to underlie the pathophysiology of schizophrenia, suggesting that promoting NMDAR activity may alleviate the negative or cognitive symptoms associated with schizophrenia. To circumvent excitotoxicity that may accompany direct agonism of the glutamate binding site on the NMDAR, therapeutic trials have focused on targeting the glycine binding site on the NMDAR. Direct administration of either glycine or D-serine, both of which are endogenous coagonists at the NMDAR glycine site, has yielded mixed outcomes across an array of clinical trials investigating different doses or patient populations.
View Article and Find Full Text PDF